Why Juno Therapeutics Shares Vaulted 46% Higher in August – Motley Fool
|
Why Juno Therapeutics Shares Vaulted 46% Higher in August
Motley Fool … with a historically poor prognosis, too. Together, these developments show chimeric antigen receptor T–cell therapy, or CAR-T, which involves reengineering a patient’s T–cells to spot and destroy cancer cells, could be the next big thing in cancer … |
News-Medical.net |
Tecan’s Freedom EVO® Platform Provides Fully Automated Cloning Solution for Synthetic Biology Research
News-Medical.net Professor Michael Tyers, who is leading the Systems Biology and Synthetic Biology Research Unit, is investigating the mechanisms of cell growth and division to unravel interactions at the genetic and proteomic levels. The information, thus gained, can … |
STAT |
Does the world really need a journal of CRISPR?
STAT n just a few years, CRISPR, the revolutionary gene editing technology, has become science’s “it” discipline, giving birth to a bitter patent dispute, billions in biotech investments, and an in-development primetime TV drama 1. But unlike the … |
Salon |
Pioneering cancer gene therapy gets green light — and $475000 price tag
Salon The country’s first approved gene therapy — approved Wednesday to fight leukemia that resists standard therapies — will cost $475,000 for a one-time treatment, its manufacturer announced. Switzerland-based Novartis, which makes the innovative therapy … |
Salon |
Pioneering cancer gene therapy gets green light and $475000 – Salon
Salon The country’s first approved gene therapy — approved Wednesday to fight leukemia that resists standard therapies — will cost $475,000 for a one-time treatment … FDA approves ‘transformative’ type of gene therapyJordan Times First gene therapy for cancer approved: What health execs should knowModernMedicine FDA approves first gene therapy in the United StatesPharmacy Today, American Pharmacists Association, pharmacist.com Shanghai Daily (subscription) all 19 news articles » |